Rick Perry & W. Bryan Hubbard

Who is Rick Perry & W. Bryan Hubbard?

Rick Perry is the former Governor of Texas and former U.S. Secretary of Energy under the Trump administration. W. Bryan Hubbard is the Chief Executive Officer of Americans for Ibogaine, a public policy education and advocacy organization dedicated to medicinalizing ibogaine in the United States. Together they discuss the potential therapeutic applications and policy implications of ibogaine as a treatment option.

Topics and Timestamps

• 01Rick Perry and W. Bryan Hubbard discuss ibogaine as a potential therapeutic treatment and the efforts to medicalize it in the United States
• 02The conversation covers the policy and regulatory challenges in bringing ibogaine into mainstream medical practice
• 03Discussion of how ibogaine differs from other psychedelic therapies and its unique applications
• 04Exploration of the intersection between traditional medicine, modern neuroscience, and drug policy reform
• 05Rick Perry's perspective on energy policy and his involvement in broader health innovation discussions
• 06The role of advocacy organizations in changing public perception and policy around unconventional treatments
• ▶Introduction of ibogaine and Americans for Ibogaine organization0:00:00
• ▶Rick Perry's perspective on drug policy and medical innovation0:15:00
• ▶Discussing ibogaine's therapeutic applications compared to other psychedelics0:35:00
• ▶Regulatory and FDA challenges in bringing ibogaine to market1:05:00
• ▶The future of psychedelic medicine policy and advocacy efforts1:45:00

The Show

This episode brings together an unlikely pairing: Rick Perry, the straight-shooting former Texas governor and energy secretary, and W. Bryan Hubbard, CEO of Americans for Ibogaine. The conversation centers on ibogaine, a naturally occurring psychoactive alkaloid with potential therapeutic applications that remains largely untapped in mainstream American medicine.

The discussion digs into why ibogaine hasn't received the attention it deserves despite growing interest in psychedelic-assisted therapy. Hubbard explains the work Americans for Ibogaine is doing to navigate the complex landscape of FDA approval, public perception, and policy reform. Unlike psilocybin or MDMA which have gained more mainstream attention recently, ibogaine remains in a gray area, with limited clinical research approved in the United States despite its use in other countries for treating addiction and other conditions.

Perry brings a practical political and policy perspective to the conversation, discussing how innovation in medicine often requires navigating bureaucratic and regulatory hurdles. The episode explores what it would actually take to get ibogaine studied properly and eventually approved as a treatment option. There's an interesting tension here between traditional government caution about controlled substances and the growing recognition that some of these compounds might have legitimate therapeutic value.

The conversation naturally touches on the broader psychedelic renaissance happening in medicine and research, with mentions of how attitudes are shifting in the scientific community. Both guests emphasize the importance of proper research, clinical trials, and evidence-based approaches rather than just casual enthusiasm for psychedelics.

What makes this episode unique is having someone with Perry's political credentials taking this conversation seriously. It signals that drug policy reform and psychedelic medicine research aren't fringe topics anymore but legitimate policy discussions that traditional political figures are engaging with. The episode manages to be both intellectually rigorous about the science while acknowledging the practical realities of changing policy and perception in America.

Best Quotes